• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥454,750 (USD4,250)||▷ お問い合わせ|
|Team User||￥508,250 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥802,500 (USD7,500)||▷ お問い合わせ|
The Crohn’s disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period. Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
Increasing awareness of Crohn’s disease, coupled with rising initiatives by regulatory bodies for the development of novel treatment options, is expected to provide the market with high growth potential.
Key Market Trends
Anti-inflammatory Agents Led the Market in 2018
Anti-inflammatory agents continued to lead as the largest sub-segment under the therapeutics segment of the market, in 2018, due to their higher efficacy, compared to immunosuppressant and analgesic. Immune system suppressors are expected to be the fastest-growing segment owing to the reduction in surgeries and hospitalization rates.
A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for the treatment of Crohn’s disease.
North America Holds the Largest Market Share
North America holds the largest market share in the Crohn’s disease diagnostics and therapeutics market, due to the increasing prevalence of Crohn’s disease in the region. Additionally, the Asia-Pacific region is expected to register high growth during the forecast period.
According to the Center for Disease Control and Prevention (CDC), it is currently estimated that about 1.3 million people suffer from inflammatory bowel disorder (IBD), in the United States. IBD prevalence includes the incidence of ulcerative colitis (UC) and Crohn’s disease. In this region, urbanization is a potential contributing factor to the increasing prevalence of Crohn’s disease. The incidence of CD is attributed to the result of the “westernization” of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals.
Overall, Crohn’s disease affects North American and Western European countries more heavily than others, with more than 750,000 people living with Crohn’s disease in the United States alone.
The Crohn’s disease diagnostics and therapeutics market has growth opportunities both in the developing and developed nations of the world. However, the US region controls a majority of the market share, which can be attributed to the higher prices of pharmaceuticals and greater prevalence of diagnosed cases of Crohn’s disease in the region. The higher share of the US market can also be attributed to the high annual cost of therapy (ACOT) of Stelara (Johnson & Johnson) and the ACOT of Risankizumab (AbbVie) in the US market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
4.2.2 Demand for Prompt Diagnosis
4.2.3 Affected Population Increasing with Time
4.3 Market Restraints
4.3.1 No Specific Treatment or Drug Available in the Market
4.3.2 Lack of Awareness among the People and Symptom Similarity with Other Gastrointestinal Diseases
4.3.3 Lack of Cost-effective Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1.1 Blood Test
5.1.2 Fecal Test
5.1.4 Flexible Sigmoidoscopy
5.1.5 Computerised Tomography
5.1.6 Magnetic Resonance Imaging
5.1.7 Other Diagnostic Tests (Capsule Endoscopy etc)
18.104.22.168 Anti-inflammatory Agents
22.214.171.124 Analgesics and Antipyretics
126.96.36.199 Other Medications
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Celgene Corporation
6.1.4 Johnson & Johnson
6.1.5 Pfizer Inc.
6.1.6 Prometheus Laboratories Inc. (Nestle)
6.1.7 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
6.1.8 Takeda’s Pharmaceutical Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS